Citius Oncology, Inc.
CTOR
$0.70
$0.022.64%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 32.84% | -32.34% | 14.56% | 29.60% | 49.36% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 43.81% | -29.35% | 6.83% | 59.25% | 39.53% |
| Operating Income | 17.87% | 29.35% | -6.83% | -59.25% | -39.53% |
| Income Before Tax | 17.59% | 29.04% | -10.30% | -59.25% | -39.53% |
| Income Tax Expenses | 0.00% | 83.47% | 83.47% | 83.47% | 83.47% |
| Earnings from Continuing Operations | 16.90% | 26.66% | -12.51% | -59.98% | -40.86% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 16.90% | 26.66% | -12.51% | -59.98% | -40.86% |
| EBIT | 17.87% | 29.35% | -6.83% | -59.25% | -39.53% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 32.01% | 34.80% | -6.08% | -50.98% | -33.00% |
| Normalized Basic EPS | 32.56% | 36.96% | -3.96% | -50.46% | -31.84% |
| EPS Diluted | 32.01% | 34.80% | -6.08% | -50.98% | -33.00% |
| Normalized Diluted EPS | 32.56% | 36.96% | -3.96% | -50.46% | -31.84% |
| Average Basic Shares Outstanding | 22.24% | 12.48% | 6.00% | 6.00% | 6.00% |
| Average Diluted Shares Outstanding | 22.24% | 12.48% | 6.00% | 6.00% | 6.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |